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Effects of Socioeconomic Status on Colon Cancer
Treatment Accessibility and Survival in Toronto,
Ontario, and San Francisco, California, 1996–2006
Kevin M. Gorey, PhD, MSW, Isaac N. Luginaah, PhD, Emma Bartfay, PhD, Karen Y. Fung, PhD, Eric J. Holowaty, MD, Frances C. Wright, MD,
Caroline Hamm, MD, and Sindu M. Kanjeekal, MD
A study of cancer survival in low-income areas
of Toronto, Ontario, and Detroit, Michigan,
during the 1980s found advantages among
Canadians for common cancers.1 The Toronto
survival advantage was replicated for breast
cancer across diverse low-income Canadian and
US contexts through the 1990s.2 Studies of that
era, however, were not able to account for
differences in stage of disease at diagnosis. More
recent studies that accounted for breast cancer
stage again found Canadian advantages.3–6 In
the United States, women with breast cancer who
lived in low-income areas waited longer for
surgery and adjuvant radiation therapy and were
less likely to receive radiation therapy or to
survive. Similar disparities between high- and
low-income women with breast cancer did not
exist in Canada; thus low-income Canadians
fared better across most breast cancer care
indices than their US counterparts. More inclu-
sive health insurance in Canada was advanced as
the most plausible explanation.
Colon cancer care may be an even more
important health care performance indicator.
The second most frequent cause of cancer
death in North America, its prognosis can be
excellent with early diagnosis and treatment.7,8
For several reasons, colon cancer seems partic-
ularly instructive for Canada–US cancer care
comparisons. First, research on income and colon
cancer survival has found moderate to strong
inverse associations in the United States but only
modest to null associations in Canada.1,9–13
Second, colon cancer screening is important, but
implementation is at an early stage in both
countries.14,15 Third, effective chemotherapies
proliferated during the 1990s for stage III
colon cancer and more recently for stage II
disease.16–18 Fourth, screening, diagnosis, and
treatment of colon cancer are more accessible to
persons with higher socioeconomic status in the
United States.18–22 Colon cancer screening is
more prevalent among higher-income persons in
Canada,23 but no previous study has examined
associations of socioeconomic status with colon
cancer treatment in that country.
Because past studies have not observed
associations between socioeconomic status and
breast cancer treatment in Canada,3–5 we
hypothesized that we would also find no signif-
icant correlation. Previous comparisons of colon
cancer survival in Canada and the United States
showed a significant advantage for Canadians
only for low-income and not for middle- or high-
income patients.1,9,24 These international studies
of colon cancer survival, however, did not
account for differences in stage at the time of
diagnosis between countries, as ours did. Be-
cause of Canada’s broad health insurance cov-
erage, we expected to find an interaction be-
tween income and country for survival. We
hypothesized that a direct income–survival gra-
dient would exist in an urban California cohort
but not in an urban Ontario cohort and that
low-income persons in Ontario would have a
survival advantage over those in urban California.
METHODS
We obtained registry data for randomly
selected, staged colon cancer cases diagnosed
between 1996 and 2000 (International Classi-
fication of Diseases, Ninth Revision code
15325) and followed until 2006 from Toronto,
Ontario (n=930), and San Francisco, CA
(n=1014). We selected these 2 cities with com-
parable populations (greater than 5 million
residents) because both had extensive health
care services, to control for cancer care service
availability.26,27 Cohorts were powered to detect
modest 5-year survival rate differences of 10%
across 3 socioeconomic strata within and between
places (2-tailed a=0.05; power1-b=0.80).28
Sampling frames were the Ontario and Cal-
ifornia cancer registries, which validly monitor the
most populous Canadian province and US state.
Objectives. We examined the differential effects of socioeconomic status on
colon cancer care and survival in Toronto, Ontario, Canada, and San Francisco,
California.
Methods. We analyzed registry data for colon cancer patients from Ontario
(n=930) and California (n=1014), diagnosed between 1996 and 2000 and
followed until 2006, on stage, surgery, adjuvant chemotherapy, and survival.
We obtained socioeconomic data for individuals’ residences from population
censuses.
Results. Income was directly associated with lymph node evaluation, chemo-
therapy, and survival in San Francisco but not in Toronto. High-income persons
had better survival rates in San Francisco than in Toronto. After adjustment for
stage, survival was better for low-income residents of Toronto than for those of
San Francisco. Middle- to low-income patients were more likely to receive
indicated chemotherapy in Toronto than in San Francisco.
Conclusions. Socioeconomic factors appear to mediate colon cancer care in
urban areas of the United States but not in Canada. Improvements are needed in
screening, diagnostic investigations, and treatment access among low-income
Americans. (Am J Public Health. 2011;101:112–119. doi:10.2105/AJPH.2009.
173112)
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Both ascertain nearly all colon cancer cases (98%
or more) with nearly perfect rates of microscopic
confirmation and nearly nil rates of death certif-
icate identification.29–32 Toronto and San Fran-
cisco oversamples were drawn (1050 each) to
account for unstaged cases and other missing
data. Only 41 of the Toronto charts were lost to
retrospective review, and these did not differ
significantly on key study variables from the
remaining 1009 that were retrieved. Insufficient
information was available to stage 79 (7.8%)
Toronto cases and 36 (3.4%) San Francisco
cases; these were excluded. This represented
a significant between-place difference (c21, 2059=
18.82; P<.05); however, the prevalence of
missing data was not significantly associated with
other key independent and dependent variables.
Therefore, sample losses were unlikely to have
confounded our study’s hypothesized relation-
ships.
Variables
For the Ontario sample, we abstracted
from hospital and physicians’ office patient
charts the same study variables that were rou-
tinely coded by the California registry.33–35
These were stage of disease at diagnosis
(according to American Joint Committee on
Cancer guidelines),34 receipt of initial surgery,
number of regional lymph nodes evaluated, re-
ceipt of adjuvant chemotherapy, and waiting
times from diagnosis to surgery and chemother-
apy. Defining characteristics of the cancer stages
were stage I (invasion into bowel wall muscle),
stage II (invasion through bowel wall muscle),
stage III (metastasized to at least1regional lymph
node), and stage IV (distally metastasized). Stage
0 or in situ tumors were not sampled. When
cancer stage was not reported, it was derived
from Surveillance, Epidemiology, and End Re-
sults extent of disease variables. Agreements
were high among 3 chart abstractors, who were
trained by an experienced cancer registrar.
Interrater assessments of 150 randomly sampled
health records found j coefficients ranging from
0.88 to 0.96 across study variables.
Similar thresholds for economic deprivation
are used by Statistics Canada (low income)
and the US Bureau of the Census (poverty).
Both are based on annual household income
adjusted for household size, but the Canadian
low-income cutoff is approximately 140% of
the US poverty threshold.36 The Canadian
measure approximates near-poverty status,
a measure of demonstrated predictive validity in
the United States.24,37 Our previous research
suggested that these 2 measures, although not
identical, would provide valid comparisons of
relatively low- to high-income urban neighbor-
hoods in the 2 countries.2,4
We first linked colon cancer patients in
Toronto and San Francisco to, respectively,
Canadian (2001) and US (2000) censuses by
their residential census tract at diagnosis.26,27
Next, to maximize predictive validity and to
match our income measures with those com-
monly used in cancer disparities research, we
delineated the following San Francisco neigh-
borhoods: high income (less than 5% of
households poor; 40% of patients), middle in-
come (5%–9% poor; 35% of patients), and
low income (10% or more poor; 25% of pa-
tients).2,4,38,39 We then delineated proportion-
ally similar Toronto neighborhoods according
to Statistics Canada’s low-income criterion.
Purchasing power–adjusted distributions of our
sample’s income tertiles in Toronto and San
Francisco are displayed in Table 1.40,41 Annual
household incomes were nearly identical in each
metropolitan area’s respective low-income
neighborhoods. Affluence was slightly more
prevalent in San Francisco.
Analyses
We used maximum likelihood logistic or
binomial regression models to estimate the
associations of demographic, prognostic, and
cancer care factors with binary 5-year (sur-
vived or not) all-cause colon cancer sur-
vival.42,43 Missing data were imputed from full
models. We estimated odds ratios (ORs) and
confidence intervals (CIs) from regression statis-
tics. After we entered all main effects into the
model, we tested the hypothesized 2-way in-
come-by-place interaction and explored all
3-way interactions (income by place by another
factor).42,44 We then described significant in-
teractions by comparing within-place colon can-
cer survival rates across income strata and
between-place survival rates within income
strata. We directly adjusted all rates by age and
stage, with our combined Toronto–San Fran-
cisco sample as the standard. We used rate ratios
(RRs) for within- and between-place compari-
sons, with 95% CIs derived from the Mantel–
Haenszel c2 test.45,46
RESULTS
Descriptive profiles of the Toronto and San
Francisco colon cancer patients in our sample
are displayed in Table 2. They were nearly
identical demographically, their unadjusted
receipt of surgical and chemotherapeutic
interventions was strikingly similar, and their
overall 5-year survival experience did not
differ significantly. Treatment waiting times of
60 or more days were more prevalent in
Toronto, but median waiting times for surgery
(Toronto, 5 days; San Francisco, 4 days) and
adjuvant chemotherapy (Toronto, 46 days; San
Francisco, 47 days) did not differ significantly.
Patients in San Francisco were more likely to
be diagnosed with localized, stage I disease and
to have more lymph nodes evaluated during
staging. In no instance was the prevalence of
missing data significantly associated with in-
come or survival. Therefore, it is unlikely that
any of the modest between-place differences in
TABLE 1—Prevalence of Low-Income or Poor Households in Colon Cancer Patients’
Neighborhoods: Toronto, ON, 2001, and San Francisco, CA, 2000
Neighborhood Income
Toronto, Prevalance of Low-Income
Households
San Francisco, Prevalence of Households
Living in Poverty
Range (Median) Income,a $ Range (Median) Income,a $
High 2.60–14.40 (9.50) 78 400 0.20–4.99 (3.20) 85 000
Middle 14.50–25.70 (19.50) 55 650 5.00–9.99 (6.60) 59 725
Low 25.80–76.50 (33.70) 41 550 10.00–49.75 (15.70) 40 850
Note. Neighborhood income derived from Statistics Canada26 and US Census27 data.
aCensus tract median annual household income in US dollars.
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missing data substantially confounded our
analyses.
Income-by-Place Interactions
The full logistic regression model for 5-year
colon cancer survival, including all main effects
and significant interactions, is displayed in
Table 3. As hypothesized, we found a strong
income-by-place interaction (OR=2.57; 95%
CI=1.47, 4.49). Among low-income patients,
Toronto residents had a significant survival
advantage (OR=2.51; 95% CI=1.52, 4.15;
interaction stratum not shown), but for middle-
and high-income patients, survival in the 2
cities did not differ significantly. We also
identified 3-way income-by-place interactions
for stage and for lymph node evaluation (Table
4).
These findings replicated several well-
known associations reported in other studies.
For example, younger age, female gender,
earlier stage of disease at diagnosis, evaluation
of more than 15 regional lymph nodes, and
receipt of surgery and chemotherapy were all
associated with better survival in this and
previous studies. After we accounted for such
demographic and clinical factors, the main
effects of income and place were both null.
Depiction of Two- and Three-Way
Interactions
Significant interactions are depicted in
Table 4. For the entire sample, survival was
associated with income in San Francisco but
not in Toronto. The 5-year survival rate was
significantly lower in San Francisco’s low-
income than in its high-income neighbor-
hoods (RR=0.84; 95% CI=0.72, 0.98).
Among high-income patients, Toronto resi-
dents had lower survival rates than did San
Francisco residents (RR=0.86; 95% CI=0.75,
0.98).
We added successive sample restrictions to
estimate the probable relative effects of ear-
lier diagnosis among high-income San Fran-
ciscans and of more accessible treatment
among low-income Torontonians. First, when
we analyzed only patients with nonlocalized,
stage II through stage IV colon cancer, the
income–survival gradient remained for San
Francisco, but the US survival advantage
among residents of high-income neighbor-
hoods was eliminated. We still found no
significant correlation for Toronto. Next, we
analyzed survival only for the most treatable
colon cancers, stages II and III. The income–
survival gradient remained for San Francisco
and was still not significant for Toronto, but
among low-income patients, the survival ad-
vantage shifted to Canadians (RR=1.23;
95% CI=0.98, 1.54).
In an analysis of stage II colon cancer only,
where recent innovations may provide clini-
cians and care managers with the most
treatment discretion, we found evidence of an
even larger Toronto survival advantage in
relatively low-income neighborhoods
(RR=1.30; 95% CI=0.98, 1.73). When we
controlled for receipt of chemotherapy
(RR=1.05; 95% CI=0.81, 1.36), our results
strongly suggested that the observed Toronto
advantage was explained by better access to
adjuvant treatment (data not shown). We
observed no significant within- or between-
place differences for stage III colon cancer
TABLE 2—Demographic and Clinical Characteristics of Colon Cancer Patients: Toronto, ON,
and San Francisco, CA, 1996–2006
Toronto, No. (%) San Francisco, No. (%)
Age at diagnosis, y
25–59 206 (22.2) 219 (21.6)
60–69 242 (26.0) 231 (22.8)
70–79 272 (29.2) 312 (30.8)
‡80 210 (22.6) 252 (24.9)
Women 466 (50.1) 505 (49.8)
Stage at diagnosisa
I 227** (24.4) 337** (33.2)
II 215 (23.1) 229 (22.6)
III 270** (29.0) 227** (22.4)
IV 218 (23.4) 221 (21.8)
Received surgery 842 (90.5) 936 (92.3)
Waiting time from diagnosis to surgery, d
< 14 610** (73.8) 609** (67.4)
14–29 125** (15.1) 205** (22.7)
30–59 58 (7.0) 69 (7.6)
‡60 33** (4.0) 20** (2.2)
Missing data 16** (1.9) 33** (3.5)
Received chemotherapy 266 (28.6) 316 (31.7)
Missing data for receipt of chemotherapy 0** (0.0) 16** (1.6)
Wait time for chemotherapy
Had chemotherapy before surgery 24 (11.3) 43 (14.0)
< 30 d after surgery 32** (15.1) 77** (25.1)
30–59 d after surgery 86 (40.6) 133 (43.3)
‡60 d after surgery 70** (33.0) 54** (17.6)
Missing data 54** (20.3) 33** (10.7)
No. of regional lymph nodes examined
< 6 304** (41.1) 274** (30.3)
6–11 282** (38.1) 312** (34.6)
12–15 68** (9.2) 151** (16.7)
‡16 86** (11.6) 166** (18.4)
Missing data 102** (12.1) 33** (3.5)
Survived 5 y from diagnosis 463 (49.8) 516 (50.9)
aAmerican Joint Committee on Cancer staging.34
**P< .05 for between-country difference (c2 test).
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(data not shown). Rates for patient refusal of
chemotherapy were similar (less than 5%) in
the 2 cities.
We also analyzed interactions of income,
place, and lymph node evaluation (Table 4). A
probable proxy for thoroughness of colon
cancer care (effective staging and treatment),
lymph node evaluation depends on the exper-
tise of both surgeons and pathologists.47–49
Patients with surgically resected stage II or III
colon cancer are the most likely to benefit from
valid staging and adjuvant chemotherapies; in
this group, lower income was associated with less
thorough lymph node evaluation in San Fran-
cisco but not in Toronto. Among high-income
patients, however, lymph node evaluation was
more thorough in San Francisco than in Toronto.
That is, staging for Torontonians was much less
likely to be based on the evaluation of more than
15 regional lymph nodes (RR=0.51; 95%
CI=0.34, 0.77). Such thorough lymph node
evaluations were associated with better 5-year
survival in both Toronto and San Francisco.
However, after modest income adjustment that
restricted the analysis to patients who resided
in middle- or low-income neighborhoods, the
lymph node evaluation–survival association
was maintained in Toronto (RR=1.40; 95%
CI=1.06,1.85), but completely eliminated in San
Francisco. This suggests that income substantially
mediates this colon cancer care–survival rela-
tionship in San Francisco but not in Toronto. It is
also likely that the Toronto survival advantage
among patients who experienced more thorough
lymph node evaluation (RR=1.46; 95%
CI=1.08, 1.97) is attributable to their better
access to indicated chemotherapies. The age-
adjusted rate of chemotherapy receipt among
middle- to low-income Toronto patients with
stage II or III colon cancer (57.3%) was much
higher than that of their counterparts in San
Francisco (34.3%; RR=1.67; 95% CI=1.06,
2.64).
DISCUSSION
To our knowledge, ours is the first report of
the effect of socioeconomic status on colon
cancer survival in similar Canadian and US
cities that accounted for disease stage. We
found strong support for our income-by-coun-
try interaction hypothesis. In within-place
comparisons, colon cancer survival in San
Francisco was significantly worse among peo-
ple living in lower-income neighborhoods.
Low-income patients in San Francisco also
experienced less thorough lymph node evalu-
ations and had less access to adjuvant chemo-
therapies. We found no associations between
socioeconomic status and colon cancer care or
survival in Toronto.
The survival advantage among high-
income persons in San Francisco was prob-
ably attributable to earlier diagnosis. The
survival advantage among low-income peo-
ple in Toronto, particularly those with the
most treatable, stage II or III colon cancer,
was very likely a result of more thorough
lymph node evaluations and better access to
indicated chemotherapies. Of interest to
both policymakers and clinicians is our
finding that after these interaction effects
were accounted for, the main effects of
income and place were no longer significant.
Socioeconomic factors appear to be associ-
ated with colon cancer care in both countries
but in different ways: high-income US pa-
tients have an advantage in prediagnostic
care and perhaps in screening, and low-
income Canadians have an advantage in
postdiagnostic care and possibly in staging
and treatment.
Our finding that colon cancer care–sur-
vival relationships were mediated by in-
come in the US cohort but not in the
Canadian cohort likely illustrates the ef-
fects of inadequate health insurance cov-
erage along with its corollaries of inacces-
sible primary care and cancer care among
America’s near poor to poor.2,50 Low-income
Canadians with colon cancer, although their risks
and vulnerabilities are similar to those of low-
income Americans, are relatively less deprived in
at least 1 critical characteristic. Their access to
medically necessary care is guaranteed through
a single-payer system. Americans receive health
care in a multitiered, multipayer system, and
some have much less access to care than others.
Our findings are consistent with those of many
US studies that observed strong relationships
between low income, absent or inadequate
health insurance, and less prevalent screening for
colon cancer, relatively later diagnosis, lack of
treatment access, and lower survival.14,51–57
Systemic health care issues, rather than personal,
biological, or cultural factors, are the most
plausible explanations for our findings because
we accounted for a key biomarker—disease stage
at diagnosis—and refusal rates for indicated
TABLE 3—Logistic Regression Results for Main Effects and Interactions of Neighborhood
Income and Place: Toronto, ON, and San Francisco, CA, 1996–2006
Predictor Variables OR (95% CI)
Significant main effects
Age at diagnosis 0.62 (0.56, 0.69)
Stage at diagnosisa 0.20 (0.16, 0.24)
Gender (female advantaged) 1.32 (1.06, 1.64)
Received surgery 3.40 (1.89, 6.12)
> 15 regional lymph nodes examined 1.57 (1.16, 2.13)
Received chemotherapy 1.53 (1.04, 2.25)
Significant interaction effects
Neighborhood income by place 2.57 (1.47, 4.49)
Neighborhood income by place by stage at diagnosis 0.67 (0.52, 0.88)
Neighborhood income by place by ‡15 nodes examined 0.20 (0.05, 0.72)
Nonsignificant main effects
Place 0.94 (0.68, 1.29)
Neighborhood income 0.94 (0.73, 1.02)
Waited ‡30 d after diagnosis for surgery 0.84 (0.59, 1.21)
Waited ‡60 d after surgery for chemotherapy 0.90 (0.75, 1.06)
Note. CI = confidence interval; OR = odds ratio. Total sample from both cities was n = 1944.
aAmerican Joint Committee on Cancer staging.34
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treatments were similar among our Canadian
and American cohorts.
Our findings are also consistent with very
low rates of colon cancer screening during
the mid-to-late 1990s. For example, fewer than
1 in 5 Ontario residents aged 50 to 59 years
were screened for colon cancer by any method
during that era.58 Cancer Care Ontario, the
agency responsible for the province’s cancer
services, instituted a colon cancer screening
program in 2007.59 It provides funding to screen
all average-risk adults aged 50 years and older
with the fecal occult blood test every 2 years and
to screen those at increased risk with colonos-
copy. Earlier colon cancer diagnoses are
expected to become more common in Ontario
in the wake of this program, and the relative
disadvantage of relatively affluent Canadians
compared with similarly affluent Americans is
expected to disappear.
Limitations
Our use of ecological measures might sug-
gest an alternate explanation for our results.
Perhaps the racial/ethnic composition of
low-income neighborhoods, rather than their
concentration of low-income households,
TABLE 4—Effects of Interactions of Socioeconomic Status and Place on Colon Cancer Care and 5-Year Survival: Toronto, ON, and
San Francisco, CA, 1996–2006
Toronto San Francisco
Toronto and San Francisco RR (95% CI)No.a (Rate) RRb (95% CI) No.a (Rate) RRb (95% CI)
SES by place on 5-year survival
All casesc
High income (Ref) 372 (0.474) 1.00 409 (0.552) 1.00 0.86** (0.75, 0.98)
Middle income 327 (0.558) 1.18 (1.02, 1.37) 358 (0.502) 0.91 (0.80, 1.03) 1.11 (0.97, 1.26)
Low income 231 (0.440) 0.93 (0.79, 1.10) 247 (0.463) 0.84** (0.72, 0.98) 0.95 (0.79, 1.15)
SES by place and stage on 5-year survival
Stage II to IV
High income (Ref) 285 (0.393) 1.00 262 (0.427) 1.00 0.92 (0.75, 1.12)
Middle income 229 (0.425) 1.08 (0.87, 1.34) 245 (0.414) 0.97 (0.82, 1.15) 1.03 (0.81, 1.30)
Low income 189 (0.399) 1.02 (0.84, 1.24) 179 (0.334) 0.78** (0.61, 1.00) 1.19 (0.92, 1.53)
Stage II and III
High income (Ref) 194 (0.546) 1.00 183 (0.563) 1.00 0.97 (0.80, 1.17)
Middle income 159 (0.586) 1.07 (0.89, 1.28) 161 (0.582) 1.03 (0.89, 1.20) 1.01 (0.80, 1.26)
Low income 132 (0.559) 1.02 (0.87, 1.19) 112 (0.454) 0.81** (0.65, 1.00) 1.23* (0.98, 1.54)
Stage II
High income (Ref) 77 (0.628) 1.00 96 (0.636) 1.00 0.99 (0.87, 1.12)
Middle income 84 (0.708) 1.13 (0.93, 1.37) 84 (0.653) 1.03 (0.84, 1.26) 1.08 (0.90, 1.30)
Low income 54 (0.711) 1.13 (0.87, 1.46) 49 (0.545) 0.86 (0.67, 2.10) 1.30* (0.98, 1.73)
SES by place on examination of > 15 regional lymph nodes
Stage II and III
High income (Ref) 191 (0.138) 1.00 178 (0.272) 1.00 0.51** (0.34, 0.77)
Middle income 158 (0.099) 0.72 (0.38, 1.38) 158 (0.165) 0.61** (0.40, 0.92) 0.60* (0.33, 1.10)
Low income 129 (0.190) 1.38 (0.87, 2.19) 110 (0.184) 0.68* (0.44, 1.06) 1.03 (0.80, 1.32)
Examination of > 15 regional lymph nodes by place on 5-year survival
< 16 nodes (Ref) 414 (0.544) 1.00 349 (0.529) 1.00 1.03 (0.88, 1.21)
> 15 nodes 64 (0.688) 1.26** (1.02, 1.55) 97 (0.614) 1.16* (0.97, 1.38) 1.12 (0.90, 1.39)
Only low- and middle-income neighborhoods
< 16 nodes (Ref) 249 (0.555) 1.00 221 (0.534) 1.00 1.04 (0.88, 1.23)
> 15 nodes 38 (0.777) 1.40** (1.06, 1.85) 47 (0.534) 1.00 (0.89, 1.13) 1.46** (1.08, 1.97)
Note. CI = confidence interval; NA = not applicable; RR = standardized rate ratio; SES = socioeconomic status. Except as noted, we directly adjusted all rates for age and stage by our sample’s
combined Toronto–San Francisco population of cases as the standard (age categories: 25–59, 60–69, 70–79, and 80 years or older; stage categories were: I, II, III, and IV). The interaction pattern
was similar for men and women (i.e., SES by place by gender and SES by place by stage by gender interactions were not significant), so rates were not adjusted for gender. Confidence intervals were
derived from the Mantel–Haenszel c2 test.
aNumber of incident breast cancer cases.
bA rate ratio of 1.00 was the within-place baseline.
cNot stage adjusted.
*P= .10; **P< 0.5.
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accounted for the between-country colon can-
cer survival differences we observed. We
believe this is unlikely for several reasons. First,
recent US studies of colon cancer treatment
and survival have consistently found that
socioeconomic differences explained most
racial-group differences.60–63 Second, although
we were not able to adjust for this factor directly
because the Ontario registry does not code race/
ethnicity, we were able to replicate key findings
by comparing the subsample of non-Hispanic
White patients in San Francisco with the entire
racially and ethnically diverse Toronto sample.
In what was perhaps the most provocative
between-place comparison—5-year survival of
low-income patients with stage II or III colon
cancer—our original analysis revealed a Toronto
advantage, and this advantage remained even
when we excluded all members of any racial/
ethnic minority group that composed more than
half of the original low-income San Francisco
sample.
Because our socioeconomic measures were
census tract aggregates that did not directly
capture individual income–colon cancer care
relationships, our findings might be seen as
ecological fallacies. We believe, however,
that census tract characteristics can serve as
proxies of community-level phenomena and
national health care access differences. An-
other question is whether the low-income
measures were adequately comparable in San
Francisco and Ontario. They were not com-
positionally identical: our income thresholds
were derived from the US Census Bureau’s
definition of poverty and Statistics Canada’s
of low income. No study has directly com-
pared the construct or predictive validities of
such ecological measures in Canada and the
United States, but their validity has been
shown in the United States,38,39,43,64 and
national censuses in both countries provided
estimates of median census tract or neighbor-
hood-level income in urban areas. In these data,
household incomes typically differed by less than
US$1000 in the low-income neighborhoods of
San Francisco and Toronto. This indicates their
similar aggregate lack of purchasing power,
which is probably also the best contextual defi-
nition of our central ecological measure. Al-
though they are probably similarly challenged to
purchase life’s necessities, residents of such
neighborhoods differ contextually in 1 important
way: Canadians in low-income neighborhoods
appear to enjoy higher-quality health care than
do similarly poor Americans.
Another possible limitation of our study was
incomplete information on outpatient treat-
ments among North American cancer regis-
tries.65,66 Such data are more difficult to collect
than inpatient data. However, the California
registry has been shown to be most complete for
chemotherapy data (84%) in San Francisco.67 In
addition, analyses of hospital-based surgery,
lymph node evaluation, and survival were un-
likely to have been affected,68 and missing
chemotherapy data were not prevalent and did
not practically differ between our Toronto and
San Francisco samples.
We focused on all-cause, rather than can-
cer-specific, survival. Cancer was the under-
lying cause of death among the vast majority
of patients with stage II and III colon cancer
in our Toronto and San Francisco samples.
The underlying cause of many deaths not
coded as cancer mortality can be directly
associated with lack of treatment or with
cancer treatment complications.69 Although
length of survival is highly accurate in cancer
registries, the underlying cause of death is not.29
Finally, although substantial death certificate
error was a likely limitation,70 our low-income,
between-place, all-cause survival comparison
was closely replicated with a cancer-specific
comparison.
Conclusions
Affluent colon cancer patients received
earlier diagnoses in San Francisco than in
Toronto, and low-income Canadians experi-
enced better investigation and treatment than
did their American counterparts. Socioeco-
nomic factors in particular appear to influence
colon cancer care in urban America. Policies
are needed to improve cancer screening, di-
agnostic investigations, and treatment access
among low-income Americans. j
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